Research ArticleDrug Discovery and Translational Medicine
Targeting Glycine Reuptake in Alcohol Seeking and Relapse
Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov and Rainer Spanagel
Journal of Pharmacology and Experimental Therapeutics April 2018, 365 (1) 202-211; DOI: https://doi.org/10.1124/jpet.117.244822
Valentina Vengeliene
Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (V.V., M.R., T.T.T., R.S.); Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland (D.A.); Department of Pharmacology, Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (B.B., A.B.); and Department of Psychopharmacology, Pavlov Medical University, St. Petersburg, Russia (A.B.)
Martin Roßmanith
Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (V.V., M.R., T.T.T., R.S.); Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland (D.A.); Department of Pharmacology, Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (B.B., A.B.); and Department of Psychopharmacology, Pavlov Medical University, St. Petersburg, Russia (A.B.)
Tatiane T. Takahashi
Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (V.V., M.R., T.T.T., R.S.); Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland (D.A.); Department of Pharmacology, Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (B.B., A.B.); and Department of Psychopharmacology, Pavlov Medical University, St. Petersburg, Russia (A.B.)
Daniela Alberati
Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (V.V., M.R., T.T.T., R.S.); Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland (D.A.); Department of Pharmacology, Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (B.B., A.B.); and Department of Psychopharmacology, Pavlov Medical University, St. Petersburg, Russia (A.B.)
Berthold Behl
Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (V.V., M.R., T.T.T., R.S.); Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland (D.A.); Department of Pharmacology, Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (B.B., A.B.); and Department of Psychopharmacology, Pavlov Medical University, St. Petersburg, Russia (A.B.)
Anton Bespalov
Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (V.V., M.R., T.T.T., R.S.); Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland (D.A.); Department of Pharmacology, Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (B.B., A.B.); and Department of Psychopharmacology, Pavlov Medical University, St. Petersburg, Russia (A.B.)
Rainer Spanagel
Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (V.V., M.R., T.T.T., R.S.); Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland (D.A.); Department of Pharmacology, Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (B.B., A.B.); and Department of Psychopharmacology, Pavlov Medical University, St. Petersburg, Russia (A.B.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
GlyT1 in Alcohol Seeking and Relapse
Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov and Rainer Spanagel
Journal of Pharmacology and Experimental Therapeutics April 1, 2018, 365 (1) 202-211; DOI: https://doi.org/10.1124/jpet.117.244822
Research ArticleDrug Discovery and Translational Medicine
GlyT1 in Alcohol Seeking and Relapse
Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov and Rainer Spanagel
Journal of Pharmacology and Experimental Therapeutics April 1, 2018, 365 (1) 202-211; DOI: https://doi.org/10.1124/jpet.117.244822
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement